Effect of oral palonosetron in improving quality of life as compared to other oral 5ht-3 antagonists in delayed cinv in patients of breast cancer

Introduction: The primary objective was to prevent delayed chemo induced nausea and vomiting (CINV). The primary efficacy end point was complete Response (CR) and improving quality of life (QOL). Material and Methods: This is a prospective, observational study conducted on 45 previously untreated histopathologically-proven patients of ductal carcinoma of Breast from January to December 2015. In this study the patients were selected based on our inclusion criteria and each cohort was composed of 15 breast carcinoma diagnosed patients, each cohort receiving Oral Ondansetron 4 mg TDS(cohort 1) ; Oral Granisetron 1 mg BD(cohort 2) ;Oral Palonosetron 0.5 mg OD(cohort 3)and after standard protocol based chemotherapy from day 3 to day 7 post chemotherapy for the prevention of Delayed CINV. and were asked to keep a vomiting diary ,interviewed on telephone and on next follow up visit and then results were graded according to the response obtained by each individual. Patients with history of allergy to 5HT-3antagonists, any associated medical condition causing nausea/vomiting were excluded. Results: A total 165 patients were included in the study, In Palonosetron Cohort 98% patients of H&N have CR and 33% in Cx in Cisplatin based chemotherapy and 64%in Anthracyclin based chemotherapy in Breast Cancer patients. Granisetron Cohort; H& N 53%, Cx 22%. Breast 84%. Ondensetron Cohort; H&N 29%, Cx 13 % Breast 57%. Conclusion: This study shows that oral Palonosetron is better than other oral 5HT-3 antagonists to prevent delayed CINV and thereby improving QOL in patients on chemotherapy.